PSI annual review: Fees, training, degrees and inspections

The PSI has released its annual report detailing its activities for the last year, including 295 risk-based inspections, training updates, and a 40% rise in fees to "ensure the viability of the organisation".

Map of Ireland with medicines in the background
(Shutterstock)

The Pharmaceutical Society of Ireland (PSI) has released its annual review, detailing changes to training and fees, and a round up of regulatory activity.

It conducted 328 pharmacy inspections in 2025, including looking at 185 matters of concern raised by the public where a formal complaint was not required.

The top three categories it looked into were practice management issues (117), behaviour/manner (59) and failure to provide a medication (20).

Formal

It also received 48 formal complaints in 2025, a decrease of 38% on the previous year, and conducted 32 onsite and one virtual registration-related inspections, an increase from 18 in 2024.

A total of 295 risk-based pharmacy inspections were conducted in 2025, including one re-inspection.

It also launched eight investigations over safety. No further action was taken in relation to seven, three pharmacists were referred to the complaints process, and two other actions were taken, including two requests for formal undertakings.

The PSI closed six investigations, leaving 18 open at the end of 2025.

In 2025, the Preliminary Proceedings Committee (PPC) considered 90 complaints relating to fitness to practise, compared with 50 complaints in 2024, an increase of 80%.

It said this increase was “largely” due to a revised approach by the PPC in 2025, where an increased number of complaints were considered at each meeting.

Of the 90 complaints, 49% were considered within the target of six months.

In 2025, 24 were referred for further action. Of these, 18 were referred to the Professional Conduct Committee, and one was referred to the Health Committee. Five complaints were referred to mediation.

Sanctions

The Council imposed 10 sanctions, with some respondents receiving multiple sanctions.

It imposed four cancellations of registration and one prohibition on restoration to the register.

Sanctions also included censure (three), admonishment (one), and the imposition of conditions (two).

Six complaints were dismissed by the Council as unsubstantiated, one complaint was withdrawn, and one appeal was made.

Net increase

During 2025, the PSI added 407 new pharmacists to the Register with 7,947 pharmacists registered at year end, representing a net increase of 216 registered between 2024 and 2025

It also held six public consultations held across a range of topics and Handled 365 regulatory and pharmacy practice queries from registrants and members of the public.

Elsewhere it launched Common Conditions Service (CCS) training for pharmacists and approved three new Masters in Pharmacy (MPharm) degree programmes.

It also launched a funding review, which has resulted in a 41.75% increase in registration fees for pharmacists.

Reserves

“Under our current corporate strategy, we committed to undertaking a core funding review, based on the impact of the operating deficit on reserves and the projections indicating that the reserves policy, approved by council, which sets a minimum threshold amount on reserves of 50% of income, would be breached in the short term,” it said.

“The PSI commissioned Forvis Mazars to carry out the review in April 2025.

“The purpose was to enable the Council of the PSI to safeguard the long-term financial stability and sustainability of the PSI, while supporting the ongoing operation of the organisation.

“A key objective of the review was to ensure that the PSI’s fee model operates on a cost-recovery basis, in line with best practice for regulatory bodies, supporting the delivery of its statutory functions to ensure public confidence in the standard of services received in pharmacies and provided by pharmacists.

“The outcome of this review is a series of recommendations, which include the application of a 41.75% increase in registration fees.”

Viability

President of the PSI, Dr Denis O’Driscoll, said as the “governing body” of the PSI, its council “plays an important role in ensuring that the organisation is appropriately resourced, strategically focused and delivering upon its remit in the public interest”.

“Our annual report documents the significant programme of work undertaken by PSI including maintaining high standards for registration, education and the delivery of pharmacy services.

“It highlights the PSI’s involvement in pursuing national initiatives that will drive patient and health service changes, progress on pharmacy workforce-related matters, and the implementation of recommendations of our core funding review, which will ensure the financial viability of the organisation.”

James Halliwell

Read more by James Halliwell

James Halliwell joined C+D as editor-in-chief in February 2024. A business journalist for the last 15 years, he’s looking forward to developing the bond between C+D and its readers and bringing them more of what they want to read, in the evolving ways they want to read it.

Latest from News

More from